Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable temporal or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eosinophil CD48 interactions with Candida albicans Als6 is protective in vitro and in mouse systemic candidiasis.

Nature communications·2025
Same author

International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreak.

PLOS global public health·2025
Same author

High rates of Dientamoeba fragilis and Blastocystis species in children's stool but minor clinical significance.

The Journal of infection·2024
Same author

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis.

Cancers·2024
Same author

Safeguarding COVID-19 vaccines: establishing the safety of novel vaccine platforms.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2024
Same author

Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2023
Same journal

[Tennis Elbow Among Players].

Harefuah·2026
Same journal

[Internal Medicine - My Mission].

Harefuah·2026
Same journal

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

Harefuah·2026
Same journal

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

Harefuah·2026
Same journal

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

Harefuah·2026
Same journal

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Harefuah·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

[AIDS--past, present and future].

Itsik Levy1, David Shasha, Zehava Grossman

  • 1Sheba Medical Center, Tel Hashomer. itsik.levi@sheba.health.gov.il

Harefuah
|May 18, 2011
PubMed
Summary
This summary is machine-generated.

Highly active antiretroviral therapy has transformed HIV into a manageable chronic condition. While a cure remains elusive, modern treatments significantly improve patient quality of life and longevity.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

Last Updated: Jun 2, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

  • Infectious Diseases
  • Virology
  • Immunology

Context:

  • Over a decade since the introduction of highly active antiretroviral therapy (HAART) for HIV.
  • Despite advancements, complete viral eradication or a universally effective vaccine remains a challenge.

Purpose:

  • To review the evolution of HIV treatment and its impact.
  • To highlight the shift in HIV management towards a chronic disease model.

Summary:

  • Introduction of safer, more effective antiretroviral drugs with high genetic barriers and improved tolerability.
  • HIV is now a manageable chronic illness, allowing patients extended lifespans with good quality of life.

Impact:

  • Significant positive influence on the epidemiological, therapeutic, psychological, and social dimensions of the AIDS epidemic.
  • Improved patient outcomes and long-term management strategies for individuals living with HIV.